Last reviewed · How we verify
Collaborative Neuroscience Research, LLC — Portfolio Competitive Intelligence Brief
1 marketed
0 filed
0 Phase 3
0 Phase 2
0 Phase 1
Live · 30-min refresh
Portfolio leaders (marketed + Phase 3 / filed)
| Drug | Generic | Phase | Class | Target | Area | First approval |
|---|---|---|---|---|---|---|
| Xanomeline and Trospium Chloride | Xanomeline and Trospium Chloride | marketed | Muscarinic M1/M4 receptor agonist with peripheral anticholinergic antagonist | Muscarinic acetylcholine receptors M1 and M4 (xanomeline); muscarinic receptors peripherally (trospium chloride antagonism) | Psychiatry / Neurology |
Therapeutic area mix
- Psychiatry / Neurology · 1
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Competitive overlap (companies sharing drug classes)
Subscribe to ongoing alerts
Every new pipeline event for Collaborative Neuroscience Research, LLC:
- Collaborative Neuroscience Research, LLC pipeline updates — RSS
- Collaborative Neuroscience Research, LLC pipeline updates — Atom
- Collaborative Neuroscience Research, LLC pipeline updates — JSON
Cite this brief
Drug Landscape (2026). Collaborative Neuroscience Research, LLC — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/collaborative-neuroscience-research-llc. Accessed 2026-05-17.